MX2023011599A - Agentes heterobivalentes y homobivalentes dirigidos a la proteína alfa de activación de fibroblastos y/o al antígeno de membrana específico de próstata. - Google Patents
Agentes heterobivalentes y homobivalentes dirigidos a la proteína alfa de activación de fibroblastos y/o al antígeno de membrana específico de próstata.Info
- Publication number
- MX2023011599A MX2023011599A MX2023011599A MX2023011599A MX2023011599A MX 2023011599 A MX2023011599 A MX 2023011599A MX 2023011599 A MX2023011599 A MX 2023011599A MX 2023011599 A MX2023011599 A MX 2023011599A MX 2023011599 A MX2023011599 A MX 2023011599A
- Authority
- MX
- Mexico
- Prior art keywords
- prostate
- homobivalent
- heterobivalent
- specific membrane
- membrane antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasonic imaging preparations
- A61K49/221—Echographic preparations; Ultrasonic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acoustics & Sound (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170035P | 2021-04-02 | 2021-04-02 | |
| PCT/US2022/023374 WO2022212958A1 (en) | 2021-04-02 | 2022-04-04 | Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011599A true MX2023011599A (es) | 2024-02-02 |
Family
ID=83459940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011599A MX2023011599A (es) | 2021-04-02 | 2022-04-04 | Agentes heterobivalentes y homobivalentes dirigidos a la proteína alfa de activación de fibroblastos y/o al antígeno de membrana específico de próstata. |
| MX2026000948A MX2026000948A (es) | 2021-04-02 | 2023-09-29 | Agentes heterobivalentes y homobivalentes dirigidos a la proteína alfa de activación de fibroblastos y/o al antígeno de membrana específico de próstata. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2026000948A MX2026000948A (es) | 2021-04-02 | 2023-09-29 | Agentes heterobivalentes y homobivalentes dirigidos a la proteína alfa de activación de fibroblastos y/o al antígeno de membrana específico de próstata. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240382629A1 (enExample) |
| EP (1) | EP4313049A4 (enExample) |
| JP (1) | JP2024514528A (enExample) |
| KR (1) | KR20230165818A (enExample) |
| CN (1) | CN117255685A (enExample) |
| AU (1) | AU2022252419A1 (enExample) |
| BR (1) | BR112023020123A2 (enExample) |
| CA (1) | CA3214070A1 (enExample) |
| IL (1) | IL307405A (enExample) |
| MX (2) | MX2023011599A (enExample) |
| WO (1) | WO2022212958A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| IL319722A (en) | 2022-09-23 | 2025-05-01 | Nuclidium Ag | High purity radionuclides and their diagnostic and medical uses |
| WO2024078592A1 (zh) * | 2022-10-14 | 2024-04-18 | 无锡诺宇医药科技有限公司 | 靶向成纤维细胞活化蛋白的药物及其应用 |
| CN118852122A (zh) * | 2023-04-27 | 2024-10-29 | 中国科学院上海药物研究所 | 一种fap抑制剂和靶向fap核素探针及其应用 |
| US12440585B2 (en) * | 2023-09-12 | 2025-10-14 | Curadel Surgical Innovations, Inc. | Zwitterionic metal chelators |
| WO2025087229A1 (zh) * | 2023-10-27 | 2025-05-01 | 四川科伦博泰生物医药股份有限公司 | 一类喹啉结构的配体化合物及其放射性或非放射性标记物以及应用 |
| KR20250062978A (ko) * | 2023-10-31 | 2025-05-08 | 서울대학교병원 | 신규한 전립선 특이적 막 항원 리간드 및 이의 용도 |
| WO2025119908A1 (en) * | 2023-12-06 | 2025-06-12 | Bracco Imaging Spa | Psma-targeting fluorescent probes |
| WO2025163029A1 (en) | 2024-01-31 | 2025-08-07 | Bracco Imaging Spa | Psma-targeting bimodal and heterobivalent fluorescent agents |
| CN117700485B (zh) * | 2024-02-04 | 2024-04-16 | 山东大学 | 一种同时靶向psma和fap的化合物及其制备方法与应用 |
| WO2025167951A1 (zh) * | 2024-02-07 | 2025-08-14 | 苏州博锐创合医药有限公司 | 一种成纤维细胞活化蛋白抑制剂 |
| US12086990B1 (en) * | 2024-04-23 | 2024-09-10 | MultiFunctional Imaging LLC | Systems and methods for simultaneous imaging of multiple positron emission tomography (PET) tracers |
| CN118271393B (zh) * | 2024-05-31 | 2024-09-03 | 中国药科大学 | 一种靶向fap的二聚化合物及其探针和应用 |
| CN119080743B (zh) * | 2024-08-30 | 2026-01-06 | 北京师范大学 | 靶向psma和fap的双重靶向化合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| JP2021500373A (ja) * | 2017-10-23 | 2021-01-07 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤 |
| PH12020551205A1 (en) * | 2018-02-06 | 2021-04-19 | Univ Heidelberg | Fap inhibitors |
| CN112088169A (zh) * | 2018-03-12 | 2020-12-15 | 纪念斯隆凯特琳癌症中心 | 双特异性结合剂及其用途 |
| KR20210116437A (ko) * | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
| CN113292538A (zh) * | 2021-05-10 | 2021-08-24 | 北京肿瘤医院(北京大学肿瘤医院) | 靶向肿瘤相关成纤维细胞激活蛋白的化合物及其制备方法和应用与靶向fap的肿瘤显影剂 |
-
2022
- 2022-04-04 US US18/553,092 patent/US20240382629A1/en active Pending
- 2022-04-04 KR KR1020237037723A patent/KR20230165818A/ko active Pending
- 2022-04-04 IL IL307405A patent/IL307405A/en unknown
- 2022-04-04 WO PCT/US2022/023374 patent/WO2022212958A1/en not_active Ceased
- 2022-04-04 AU AU2022252419A patent/AU2022252419A1/en active Pending
- 2022-04-04 EP EP22782372.1A patent/EP4313049A4/en active Pending
- 2022-04-04 CA CA3214070A patent/CA3214070A1/en active Pending
- 2022-04-04 JP JP2023560919A patent/JP2024514528A/ja active Pending
- 2022-04-04 CN CN202280032772.6A patent/CN117255685A/zh active Pending
- 2022-04-04 MX MX2023011599A patent/MX2023011599A/es unknown
- 2022-04-04 BR BR112023020123A patent/BR112023020123A2/pt unknown
-
2023
- 2023-09-29 MX MX2026000948A patent/MX2026000948A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023020123A2 (pt) | 2024-01-23 |
| JP2024514528A (ja) | 2024-04-02 |
| CA3214070A1 (en) | 2022-10-06 |
| EP4313049A4 (en) | 2026-01-21 |
| KR20230165818A (ko) | 2023-12-05 |
| CN117255685A (zh) | 2023-12-19 |
| EP4313049A1 (en) | 2024-02-07 |
| IL307405A (en) | 2023-12-01 |
| MX2026000948A (es) | 2026-03-02 |
| US20240382629A1 (en) | 2024-11-21 |
| AU2022252419A1 (en) | 2023-10-19 |
| WO2022212958A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023020123A2 (pt) | Agentes heterobivalentes e homobivalentes que alvejam proteína alfa de ativação de fibroblasto alfa e/ou antígeno de membrana específico da próstata | |
| MX2020004807A (es) | Agentes radioterapeuticos y de imagenologia que se dirigen a proteina-alfa de activacion fibroblastos (fap-alfa). | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| MX2021004775A (es) | Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt). | |
| PE20230849A1 (es) | PROTEINAS DE FUSION INTERLEUCINA-2-Fc Y METODOS DE USO | |
| MX387358B (es) | Variantes de il-15 y usos de las mismas | |
| CL2024002093A1 (es) | Anticuerpos anti-cd73. | |
| MX2021014601A (es) | Proteinas recombinantes de union a fap y su uso. | |
| SA522432487B1 (ar) | مشتقات علاجية من إنترلوكين-22 | |
| PH12023550032A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| CY1124916T1 (el) | Υγρο σκευασμα νευροτοξινης σταθεροποιημενο με τρυπτοφανη ή τυροσινη | |
| CY1111714T1 (el) | Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf). | |
| CL2024000459A1 (es) | Tubulisinas y conjugados de proteína-tubulisina. | |
| EP4192962A4 (en) | CSRP3 (CYSTEINE-GLYCINE RICH PROTEIN 3) GENE THERAPY | |
| WO2021181233A3 (en) | Cd80-fc fusion protein and uses thereof | |
| BR112023002455A2 (pt) | Anticorpos fgfr3 e métodos de uso | |
| ECSP15028696A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos | |
| CY1124183T1 (el) | Συζευγματα αντισωματος εναντι-sez6 φαρμακου και μεθοδοi χρησης | |
| BR112021025699A2 (pt) | Anticorpos anti-mesotelina e imunoconjugados dos mesmos | |
| BR112021017810A2 (pt) | Anticorpos tsg-6 e usos dos mesmos | |
| CL2025001214A1 (es) | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos | |
| CO2020014681A2 (es) | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas | |
| CL2022002577A1 (es) | Aparato para eficiencia de transfeccion mejorada y/o expresion de proteina y metodo de uso del mismo. | |
| CO2025009742A2 (es) | Tratamiento de la enfermedad autoinmunitaria | |
| MX2022001626A (es) | Composiciones biofarmaceuticas y procedimientos conexos. |